Bacellar Costa Lima A, Macedo LT and Deeke Sasse A: Addition of bevacizumab to chemotherapy in advanced nonsmall cell lung cancer: A systematic review and meta-analysis. Plos One 6(8): e22681, 2011.
Stinchcombe TE and Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6(2): 233-241, 2009.
Shiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Eng J Med 346(2): 92-98, 2002.
Gettinger S: Targeted therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 29(3): 291-301, 2009.
Ulahannan SV and Brahmer JR: Antiangiogenetic agents in combination with chemotherapy in patients with advanced nonsmall cell lung cancer. Cancer Investigation 29: 325-337, 2011.
Blau HM and Banfi A: The well-tempered vessel. Nat Med 7(5): 532-534, 2001.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1): 4-6, 1990.
Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4): 273-286, 2007.
Jain RK: Normalizing tumor vasculature with anti-angiogenetic therapy. Nat Med 7(9): 987-989, 2001.
Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438(7070): 967-974, 2005.
Carmeliet P and Jain NK: Angiogenesis in cancer and other diseases. Nature 407(6801): 249-257, 2000.
Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3): 4-10, 2005.
Gridelli C, Maione P, Rossi A and De Marinis F: The role of bevacizumab in the treatment of non-amall cell lung cancer: Current indications and future developments. Oncologist 12: 1183-1193, 2007.
Jenab-Wolcott J and Giantonio BJ: Bevacizumab current indications and future development for management of solid tumors. Expert Opin Biol Ther 9(4): 507-517, 2009.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Graudreault J, Damico LA, Holgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22(11): 2184-2191, 2004.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Eng J Med 355(24): 2542-2550, 2006.
Reck M, Von Pavel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 27(8): 1227-1234, 2009.
Mezger J, Von Pavel J and Reck M: Bevacizumab (Bv) single agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Result from an exploratory analysis of the AVAiL study. J Clin Oncol 27 (15S, May 20 suppl): Abstract e19001, 2009.
Patel JD, Hensing TARademaker A, Hart EM, Blum MG, Milton DT and Bonomi PD: Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for non-squamous non-small cell lung cancer. J Clin Oncol 27(20): 3284-3289, 2009.
Patel J, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Hermann RC, Liu J, Guba SC, Bonomi P and Govindan R: A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (NS-NSCLC). J Thor Oncol 7(15): S336-S338, 2012.
Socinski MA, Patel JD, Garon EB, Govindan R, Reynolds CH, Spigel DR, Olsen MR, Liu J, Guba SC and Bonomi P: A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance Pem plus Bev versus paclitaxel (Pac) plus Cb plus Bev followed by maintenance Bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results. J Clin Oncol 31 (suppl; abstr 8004), 2013.
Barlesi F, De Castro J, Dvornichenko V, Kim JH, Pazzola A, Rittmeyer A, Vikström A, Mitchell L, Wong EK and Gorbunova V: AVAPERL (MO22089): Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (Bev) or Bev + pemetrexed (Pern) after first-line (1L) Bev-cisplatin (Cis)-Pem treatment (Tx). Eur J Cancer 47(Suppl 2): 16, 2011.
Rittemeyer A, Scherpereel A, Gorbunova VA, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts J, Groen HJM, Morando C, Loundou A and Barlesi F: Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (Pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 31 (suppl; abstr 8014), 2013.
Skaff ZG, Hageboutros A, Krieger K, Coakley S, Somer R and Stevenson J: A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 27(15S): Abstract e19091, 2009.
Dalsania CJ, Hageboutros A, Harris E, Krieger K, Vora C and Stevenson J: Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous nonsmall cell lung cancer. J Clin Oncol 25(18S): Abstract 18163, 2007.
Waples JM, Auerbach M, Steis R, Boccia RV and Wiggans RG: A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04-015). J Clin Oncol 26(15S): Abstract 19018, 2008.
Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ, Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen W, Heilbrun LK and Ruckdeschel JD: A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27(15S): Abstract e19099, 2009.
Lilebaum R, Racz L, Tseng J, Scigel L and Davila E: Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 3 (5): 511-515, 2008.
Leon L, Vazquez S Gracia JM, Lazaro M, Firvida JL, Casal J, Amenedo M, Santome L, Gallego R and Anido U: Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naïve patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 27(15S): Abstract e19089, 2009.
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M and Sandler A: A phase II study of efficacy and safety of bevacizumab in combination with chemotherapy alone for treatment of recurrent or refractory nonsmall cell lung cancer. J Clin Oncol 25(30): 4743-4750, 2007.
Ferrer N, Cobo M, Paredes A, Mendez M, Munoz-Langa J, Rueda A, Alverez de Mon M, Sanchez-Hernandez A, Gallego R and Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 27(15S): Abstract e19023, 2009.
Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S and Asmar L: Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in firstline patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 4 (12): 1537-1543, 2009.
Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, Mc Millan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD and Wakelee IIA: A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol 5(11): 1821-1825, 2010.
Bordonaro R, Soto-ParraH, Giannitto-Giorgio C, Cinieri S, Latteri F, Sergi C, Pappagallo GL, Cordio SS, Salice P, Sambataro D and Potenza E: Activity and safety of CPBev regimen (cisplatinum, pemetrexed, and bevacizumab) as first-line therapy for locally advanced or metastatic adenocarcinoma of the lung: finalresults of a phase II study. J Clin Oncol 30 (suppl; abstr e18026), 2012.
Lopez-Vivanco G, Carrera S, Sancho A, Marrodan I, Azcona E, Iruarrizaga E, Rubio I, Muñoz A and Cardona JV: Bevacizumab (B), cisplatin (C), and pemetrexed (P) plus maintenance B in chemonaive patients (pts) with advanced nonsquamous nonsmall cell lung cancer (nsNSCLC): A phase II study. J Clin Oncol 30 (suppl; abstr e18031), 2012.
Guarino MJ, Masters GA, Biggs D, Schneider C, Ghazi Misleh J, Simpson PS, Suppiah K, Wozniak TF and Grubbs SS: Phase II trial of carboplatin, pemetrexed, and bevacizumab in metastatic nonsquamous (NSC) lung cancer. J Clin Oncol 30 (suppl; abstr e18122), 2012.
Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers jp, Adjei A, Mandrekar SJ and Adjei AA: N0821: a phase II firstline study of a combination of pemetrexed (P), carboplatin (C) and bevacizumab (B) in elderly patients with good performance status (PS<2). J Clin Oncol 30 (suppl; abstr 7555), 2012.
West HJ, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Joseph Bury M, Weber Redman M and Gandara DR: SWOG S0635 and S0636: Phase II trial in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). J Clin Oncol 30 (suppl; abstr 7517), 2012.
Yoshino R, Kaiara K, Tomizawa Y, Kazama T, Yoshii A, Miura Y, Ishihara S, Fueki N, Minato K and Sunaga N: Phase II stidy of bevacizumab in combination with S-1 plus cisplatin in patients with advanced nonsquamous non-small cell lung cancer. J Clin Oncol 30 (suppl; abstr e18037), 2012.
Kaneda H, Urata Y, Okamoto I, Hattori Y, Okuno K, Shimada T, Takeda M, Kurata T, Miyazaki M, Terashima M, Tanaka K, Kiyota H, Hayashi H, Kudo T, Okabe T, Azuma K, Morita S, Nakagawa K, Negoro S and Satouchi M:: Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemonaïve patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 30 (suppl; abstr e18060), 2012.
Ohyanagi F, Tanimoto A, Sakatani T, Kawano Y, Saito R, Kaburaki K, Yanagitani N, Kudo K, Horiike A, Hagiwara S, Horai T and Nishio M: Phase II trial of bevacizumab plus docetaxel in patients with previously treated nonsquamous non-small cell lung cancer. J Clin Oncol 30 (suppl; abstr e18004), 2012.
Habib S, Delourme J, Dhalluin X, Scherpereel A, Lafitte JJ and Cortot AB: Weekly paclitaxel and bevacizumab as fourth-line treatment or beyond for metastatic nonsquamous non-small cell lung cancer. J Clin Oncol 30 (suppl; abstr e18066), 2012.
Gridelli C, Bennouna J, De Castro J, Dingemans AMC, Griesinger F, Grossi F, Thatcher N, Ohe Y, Perez-Moreno PD and Langer CJ: AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous nonsmall cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT). J Clin Oncol 30 (suppl; abstr TPS7612). 2012.
Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6): 713-718, 2007.
Crinò L, Dansin E, Garrido P, GriesingerF, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL and Zhou C: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11(8): 733-740, 2010.
Fishbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A and Lynch T, for the ARIES investigators: Preliminary safety and effectiveness of bevacizumab (Bv)-based treatment in subpopulation of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab Bv treatment observational cohort study (OCS) J Clin Oncol 27(15S): Abstract 8040, 2009.
Polikoff J, Hainsworth JD, Fehrenbacher L, Royer-Joo S, Mu Y, Strickland DK and Miller VA. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with nonsmall cell lung cancer (NSCLC) treated on ATLAS. J Clin Oncol 26(15S): Abstract 8079, 2008.
Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L and Akerley W: Safety of bevacizumab in patients with non-small cell lung cancer and brain metastases. J Clin Oncol 27: 5255-5261, 2009.
Otterson GA, O'Connor PG, Lin M and Herbst RS, for the BETA Lung Investigators: Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. J Clin Oncol 27(15S): Abstract e19025, 2009.
Besse B, Le Moulec S, Senellart H, Mazieres J, Barlesi F, Dansin E, Robinet G, Perol M, Moro-Sibilot D and Soria JC: Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). J Clin Oncol 31 (suppl; abstr 8059), 2013.
Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S and Spigel GL: Predicting and managing the risk of pulmonary hemorrhage in patirnts with NSCLC treated with bevacizumab: A consensus report from a panel of expert. Ann Oncol 23: 1111-1120, 2012.
Hainsworth JD, Fang L, Huang JE, Karlin D, Russel K, Faoro L and Azzoli C: BRIDGE: an open label phase IItrial evaluating the safety of bevacizumab+ carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated squamous nonsmall cell lung cancer. J Thorac Oncol 6: 109-114, 2011.
Griesinger F, Bearz A, Eberhardt W, Garrido P, Isla D, Ko Y, Kohlhaufl M, Schneider C, Thatcher T and Palakis N: Safety of first line bevacizumab (BV)-based therapy in the SAiL (MO19390) trial: Central trumor location (CTL) and hypertension (HTN) in patients (PTS) with advanced non-small cell lung cancer (NSCLC). Ann Oncol 21(Suppl 8): viii 144, 2010.
Kumar P, Fishbach NA, Brahmer JR, Spigel DR, Beatty S, Teng S, Flick ED, Sing A and Lynch TJ: Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab ((BV).treated non-small cell lung cancer (NSCLC) patients (pt): results from ARIES, an observational cohort study (OCS). J Clin Oncol 28 (Suppl): 15s (Abstr 7619), 2010.
Sandler AB, Schiller JH, GrayR, Dimery I, Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 27: 1405-1412, 2009.
Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Stewart DJ, Jimenez CA, Blumenschein GR and Onn A: Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3: 351-357, 2008.
Besse B, Laserre SF, Compton P, Huang J, Augustus S and Rohr UP: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16: 269-278, 2010.
Hood JD, Meininger CJ, Ziche M and Granger HJ: VEGF upregulates ecNOS message, protein and NO production in human endothelial cells. Am J Physiol 274: H1054-1058(suppl 3), 1998.
Mourad JJ, Guetz G, Debbabi H and Levy BI: Blood pressure rise following angiogenesis inhibition by bevacizumab: A crucial role for microcirculation. Ann Oncol 19: 927-934, 2008.
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH and Johnson DH: Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28: 949-954, 2010.
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J and Small EJ: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28(13): 2137-2143, 2010.
Leighl NB, Zatloukal P, Mezger J, Ramlau R, Reck M and Menegold C: Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous nonsmall cell lung cancer in the phase III BO17704 study (AVAIL). J Thorac Oncol 5(12): 1970-1976, 2010.
Chun -Ru C and Ya-Chen TS: Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). Clin Econom Outcomes Res 4: 201-208, 2012.
Chouaid C, Atsou K, Hejblum G and Vergnenegre A: Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 27(2): 113-125, 2009.
Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF and Walzer S: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon Outcomes Res 4: 31-37, 2012.
Bongers ML, Coupé VM, Jansma EP, Smit EF and Uyl-de Groot CA: Cost effectiveness of treatment with new agents in advanced non-small cell lung cancer: A systematic review. Pharmacoeconomics 30(1): 17-34, 2012.
Isla D, González-Rojas N, Nieves D, Brosa M and Finnern HW: Treatment patterns, use of resources, and costs of advanced nonsmall cell lung cancer patients in Spain: Results from a Delphi panel. Clin Transl Oncol 13(7): 460-471, 2011.
Bischoff HG, Heigener DF, Walzer S and Nuijten M: Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 69(Suppl 1): S18-S23, 2010.
Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de Castro Carpeño J, Chouaid C, Walzer S, Mueller E and Schmidt: Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer 69(Suppl 1): S24-S30, 2010.
Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R and Schwartzberg L: Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 4(11): 1404-1414, 2009.
Klein R, Wielage R, Muehlenbein C, Lepa AM, Babineaux S, Lawson A and Schwartzberg L: Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 5(8): 1263-1272, 2010.
Giuliani G, Grossi F, de Marinis F and Walzer S: Costeffectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 69(Suppl 1): S11-S17, 2010.
Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JWC, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J and Walzer S: Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced nonsquamous NSCLC in Korea and in Taiwan. Asia-Pacific J Clin Oncol 7(suppl 2): 22-33, 2011.
Goulart B and Ramsey S: A trial-based assessment of the costutility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14(6): 836-845, 2011.
